Deep Protein Profiling Key To Improving Cancer Treatment
As global experts in mapping and analysis of protein changes in systems-wide biology, Proteome Sciences plc is strongly encouraged by two recent reports that emphasize the importance of protein profiling to improve outcomes in cancer treatment.
Trading Update
After closing 2015 with a good increase in revenues in the second half, the current year has started well with a strong order book and a growing pipeline in biomarker services.
Director Dealing
The Company has received notification from Vulpes Life Sciences Fund (“Vulpes”) that it has a total direct and indirect interest in 36,573,125 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) equivalent to 16.04% of Proteome Sciences’ total issued share capital.
CK1d Inhibitors Reduce Alzheimer’s Tau Phosphorylation
From the 8th Clinical Trials on Alzheimer’s Disease in Barcelona, PS announces that a recently completed study testing its proprietary inhibitors of CK1d reduced the level of tau phosphorylation in a second in vivo model of Alzheimer’s disease tauopathy.